BioSpace News Archive

Cynata Therapeutics Limited (ASX: CYP), a clinical-stage biotechnology company specialising in cell therapeutics, is pleased to announce that it has received approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) to proceed with its Phase 2 clinical trial of the Cymerus™ mesenchymal stem cell (MSC) product CYP-002 in patients with critical limb ischaemia (CLI).

Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on the development of therapeutics that modulate the endocannabinoid system, today reported financial and operating results for the first quarter of its fiscal year ended November 30, 2019.

Lumagenics, today announced that veteran technology executive Steve Grenon has joined the company as Chief Operating Officer.

Celsee, Inc., a leading provider of single-cell isolation technology, and Kindstar Global, the largest medical esoteric testing service group in China, announced a purchase agreement to provide scientists at the Kindstar Laboratory System in China with Celsee’s Genesis System for monitoring circulating tumor cells in lung, breast, and bladder cancers as well as single-cell research.

Addition of 35-Year Pharmaceutical Industry Veteran Augments Board’s Business Development and Commercial Strategy Expertise

A2A Pharmaceuticals Inc. announced an agreement to design and co-develop oncology drug candidates with Daewoong Pharmaceutical Co., Ltd., a major pharmaceutical company in South Korea, using its proprietary AI-enabled drug discovery platform SCULPT™.

Collaboration with Tor Vergata University Hospital of Rome Will Be Used to Discover New Mechanisms and Biomarkers in Cancer

Distributed Bio, a global leader in computational optimization of fully human monoclonal antibody libraries, is pleased to announce a multi target research collaboration with John DiPersio, MD, PhD, Chief of the Division of Oncology at Washington University School of Medicine and Deputy Director of the Alvin J. Siteman Cancer Center in St. Louis.

ICON plc, global provider of outsourced drug and device development and commercialisation services to pharmaceutical, biotechnology, medical device and government and public health organisations, announced its financial guidance for the year ended December 31, 2020.

Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative hematology solutions to drive better patient outcomes, today announced that it has purchased the technology underlying the TEG® 6s Hemostasis Analyzer System from CoraMed Technologies, LLC.